Methotrexate update

Scandinavian Journal of Rheumatology

Volumn 25, Issue 6, 1996, Pages 341-344

  Kremer, J M ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

folate; kidney; liver; lung; mechanism of action; methotrexate; rheumatoid arthritis

Indexed keywords

FOLIC ACID; FOLINIC ACID; METHOTREXATE;

CLINICAL TRIAL; HUMAN; LIVER TOXICITY; LUNG TOXICITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0030470716     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749609065644     Document Type: Review

References (31)

1. Alarcón GS, Tracy IC, Blackburn WD Jr. Methotrexate in Rheumatoid Arthritis: Toxic Effects as the Major Factor in Limiting Long-Term Treatment. Arthritis Rheum 1989; 32: 671-6.
2. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The Effect of Folic Acid Supplementation on Toxicity of Low-Dose Methotrexate in Patients With Rheumatoid Arthritis. Arthritis Rheum 1990; 33: 9-18.
3. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, et al. Supplementation With Folic Acid During Methotrexate Therapy for Rheumatoid Arthritis. A Double-Blind Placebo Controlled Trial. Ann Intern Med 1994; 121: 833-41.
4. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of Rheumatoid Arthritis in Patients Treated With Methotrexate After Administration of Folinic Acid. Ann Rheum Dis 1991; 50: 913-4.
5. Tishler M, Caspi D, Fishel B, Yaron M. The Effects of Leucovorin (Folinic Acid) on Methotrexate Therapy in Rheumatoid Arthritis Patients. Arthritis Rheum 1988; 31: 906-8.
6. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-Dose Methotrexate With Leucovorin (Folinic Acid) in the Management of Rheumatoid Arthritis. Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheum 1993; 36: 795-803.
7. Weinblatt ME, Maier AL, Coblyn JS: Low-Dose Leucovorin Does Not Interfere With the Efficacy of Methotrexate in Rheumatoid Arthritis: An 8 Week Randomized Placebo Controlled Trial. J Rheumatol 1993; 20: 950-2.
8. Furst DE, Koehnke R, Burnmeister LF, et al. Increasing Methotrexate Effect With Increasing Dose in the Treatment of Resistant Rheumatoid Arthritis. J Rheumatol 1989; 16: 313-20.
9. Weinblatt ME, Coblyn JS, Fox DA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. N Engl J Med 1985; 312: 818-22.
10. Williams JH, Willkins RF, Samuelson Co Jr, Alarcon GS, Guttadauria M, Yarboro C, et al. Comparison of Low-Dose Oral Pulse Methotrexate and Placebo in the Treatment of Rheumatoid Arthritis: A Controlled Clinical Trial. Arthritis Rheum 1985; 28: 721-30.
11. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly Pulse Methotrexate in Rheumatoid Arthritis: Clinical and Immunologic Effects in a Randomized, Double-Blind Study. Ann Intern Med 1985; 103: 489-96.
12. Furst DE, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA: Adverse Experience With Methotrexate During 176 Weeks of a Long-Term Prospective Trial in Patients With Rheumatoid Arthritis. J Rheumatol 1990; 17: 1628-35.
13. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, et al. Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis: 84-Month Update. Arthritis Rheum 1992; 35: 129-37.
14. Kremer JM, Phelps CT. Long-Term Prospective Study of the Use of Methotrexate in the Treatment of Rheumatoid Arthritis: Update After a Mean of 90 Months. Arthritis Rheum 1992; 35: 138-45.
15. Nyfors A. Liver Biopsies From Psoriatics Related to Methotrexate Therapy: 3. Findings in Post-Methotrexate Liver Biopsies From 160 Psoriatics. Acta Pathol Microbiol Scand [A] 1977; 85: 511-8.
16. Zachariae H, Kragballe K, Sogaard H. Methotrexate Induced Liver Cirrhosis Studies Including Serial Liver Biopsies During Continued Treatment. Brit J Dermatol 1980; 102: 407-12.
17. Weinstein GD, Reonigk H, Maibach HI, Weinstein G, Cosmides J, Halperin K, et al. Psoriasis-Liver-Methotrexate Interactions. Arch Dermatol 1973; 108: 36-42.
18. Walker AM, Punch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, et al. Determinants of Serious Liver Disease Among Patients Receiving Low-Dose Methotrexate for Rheumatoid Arthritis. Arthritis Rheum 1993; 36: 329-35.
19. Kremer LM, Lee RG, Tolman KG. Liver Histology in Rheumatoid Arthritis Patients Receiving Long-Term Methotrexate Therapy: A Prospective Study With Baseline and Sequential Biopsy Samples. Arthritis Rheum 1989; 32: 121-7.
20. Kremer JM, Kaye GI. Electron Microscopic Analysis of Sequential Liver Biopsy Samples From Patients With Rheumatoid Arthritis: Correlation With Light Microscopic Findings. Arthritis Rheum 1989; 32: 1202-13.
21. Kremer JM, Kaye GI, Kaye NW, Ishak KG, Axiotiz CA. Light and Electron Microscopic Analysis of Sequential Liver Biopsy Samples From Patients With Rheumatoid Arthritis Receiving Long-Term Methotrexate Therapy: Follow-Up Over prolonged Treatment Intervals and Correlation With Clinical and Laboratory Variables. Arthritis and Rheum 1995; 38: 1194-1203.
22. Kremer JM, Furst D, Weinblatt ME, Blotner SD. Significant Changes in Serum AST Across Hepatic Histological Biopsy Grades: An Analysis of 3 Prospective Cohorts on Methotrexate Therapy for Rheumatoid Arthritis. J Rheum 1996; 23: 459-61.
23. Kremer JM, Alarcon GS, Lightfoot RW, Wilkens RF, Furst DE, Williams HJ, et al. Methotrexate for Rheumatoid Arthritis: Suggested Guidelines for Monitoring Liver Toxicity. Arthritis and Rheum 1994; 37: 3:316-28.
24. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in Psoriasis: Revised Guidelines. J Am Acad Dermatol 1988; 19: 145-56.
25. Kremer JM, Alarcón GS, Alexander RW, Cannon GW, et al. Methotrexate (MTX) Lung Toxicity: Clinical Features of Thirty-Seven Cases From Seven Rheumatology Practices. Arthritis Rheum 1995; 37: s205.
26. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and Renal Function in Patients With Rheumatoid Arthritis Receiving a Standard Dose of Oral Weekly Methotrexate Over a Period of 24 Months: Association With Significant Decreases in Creatinine Clearance and Renal Clearance of the Drug. J Rheumatol 1995; 22: 38-40.
27. Kremer JM, Petrillo GF, Hamilton RA. The Effects of Non-Steroidal Anti-Inflammatory Drugs on Methotrexate Pharmacokinetics: Impairment of Renal Clearance of MTX at Weekly Maintenance Doses but not at 7.5 mg. J Rheum 1995; 22: 2072-7.
28. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G. et al. Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis. N Engl J Med 1995; 333: 137-41.
29. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff J, et al. Treatment of Rheumatoid Arthritis With Methotrexate Alone, Sulfasalazine and Hydrochloroquine, or a Combination of All Three Medications. N Engl J Med 1996; 334: 1287-91.
30. Hamilton RA, Kremer JM. Why Intramuscular Methotrexate May be More Efficacious Than Oral Dosing in Patients With Rheumatoid Arthritis. Brit J Rheum (in press), 1996.
31. Kremer JM. The Mechanism of Action of Methotrexate in Rheumatoid Arthritis: The Search Continues. J Rheumatol 1994; 21: 1-5.